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Introduction
Effectiveness of gene therapy for various diseases has recently been examined intensively not only in animal models but also in humans. In vivo gene therapy is definitely more promising for clinical applications, because ex vivo gene therapy requires invasive surgical procedures to collect target cells for genetic modification. Adenoviral vectors are ideally suited for in vivo gene transfer applications due to their high titers, ability to target a wide range of both dividing and nondividing cells, and their ability to mediate a high level of transgene expression. Adenovirus serotype-2 and -5, which cause respiratory diseases in humans, have been developed for use in gene therapy; both belong to a subclass of adenovirus that is not associated with human malignancies. 1 The natural tropism of adenoviruses for airway epithelia has been exploited in the development of gene therapy for cystic fibrosis. [2] [3] [4] Another application of recombinant adenoviruses, not expected by the usual spectrum of naturally acquired infections, has been for liver-directed gene therapy. Recombinant adenoviruses infused directly into the circulation primarily target hepatocytes. [5] [6] [7] [8] [9] Correspondence: S Kuriyama Received 12 August 1998; accepted 21 December 1998 Despite these advances of adenoviral vectors, several factors significantly limit the utility of current early gene region 1 (E1)-deleted adenoviral vectors. Persistence of transgene expression in vivo is limited to 2-3 weeks due, at least in part, to destruction of adenoviral vector-transduced cells by host cellular immune responses directed against viral proteins and/or immunogenic transgene products. [10] [11] [12] Extensive in vivo gene transfer studies with E1-and E1/E3-deleted adenoviral vectors have demonstrated expression of viral late gene products leading to direct cytopathic effects of target cells shortly after gene transfer and host cellular immune responses against viral proteins, 13-16 both leading to inflammation and destruction of transduced tissues.
Another important limitation of current adenoviral vectors is the difficulty in obtaining successful readministration using a vector of the same adenovirus serotype. Several studies have indicated that neutralizing antibodies elicited by input viral particles reduce the efficiency of vector readministration, 11, 12, 17, 18 which is expected to be necessary for the chronic treatment of genetic disorders such as cystic fibrosis. It should be noticed that humans are natural hosts of various serotypes of adenovirus and that the majority of humans possess neutralizing antibodies against adenoviruses serotype-2 and -5. Therefore, the first administration of adenoviral vectors to gene therapy patients who have been exposed to wild-type adenoviruses may correspond to the readministration of adenoviral vectors into animals. Injection of a recombinant adenovirus into adenovirally immunized subjects would be expected to produce a strong secondary immune response, resulting in rapid clearance of the virus and cytotoxic T lymphocyte invasion of the tissues infected by the recombinant virus. It is, therefore, an important issue for clinical applications of recombinant adenoviruses to examine whether adenoviral administration can induce transgene expression in immunized animals. Recently, Ilan et al 19 have shown that oral administration of adenoviral antigens into immunized rats prevented a booster response upon subsequent readministration of recombinant adenoviruses and resulted in the transfer and expression of the transgene.
In the present study, rats were infused intraportally with recombinant adenoviruses carrying a reporter lacZ gene and the duration of transgene expression was estimated. Furthermore, we examined whether transient cyclophosphamide (CPA) treatment before intraportal readministration of adenoviruses can induce reexpression of the original gene construct in the rat liver.
Results

Duration of lacZ gene expression in the liver
To study the duration of transgene expression in the liver induced by intraportal infusion of adenoviruses, 2 × 10 9 plaque-forming units (p.f.u.) of recombinant adenoviruses, Adex1CAlacZ, carrying the Escherichia coli ␤-galactosidase gene, lacZ, under the control of the CAG promoter composed of the cytomegalovirus enhancer plus the chicken ␤-actin promoter, contained in a 500-l inoculum volume were infused intraportally into rats. Intraportal infusion of this amount of adenoviruses into rats was, however, shown to be extremely toxic, resulting in the death of four of six animals within 7 days after the infusion. We therefore decreased the viral amount infused into the portal vein from 2 × 10 9 p.f.u./500 l to 2 × 10 8 p.f.u./500 l. When rats received intraportal infusion of 2 × 10 8 p.f.u. of adenoviruses, no animal died within a 60-day observation period.
Expression of the lacZ gene in the liver of animals infused with 2 × 10 8 p.f.u. of adenoviruses was examined. Although it is difficult to estimate accurately the rate of cells expressing the lacZ gene in the liver, morphometric evaluation of liver sections made by using the public domain NIH Image program written by Wayne Rasband at the National Institutes of Health (Bethesda, MD, USA) revealed that approximately 10% of cells expressed the lacZ gene at day 2 after the infusion (Figure 1a) . At day 7, approximately 60-70% of cells in the liver were stained blue with the X gal staining (Figure 1b) . However, cells expressing the lacZ gene were markedly decreased at day 14 after the infusion (Figure 1c ) and there were no cells expressing the lacZ gene at day 35 (data not shown).
To estimate quantitatively lacZ gene expression in the liver induced by intraportal infusion of adenoviruses, ␤-galactosidase activity was measured using the ONPG assay. Recombinant adenoviruses carrying the lacZ gene (2 × 10 8 p.f.u./500 l) were infused into the portal vein of rats. At various time-points, livers were removed from animals and examined for ␤-galactosidase activity. As shown in Figure 2 , considerable levels of lacZ gene expression were observed in the liver at day 2 after the infusion, with ␤-galactosidase activity being 10.5 ± 2.1 units. Expression of the lacZ gene in the liver further increased at day 7, with ␤-galactosidase activity being 56.2 ± 17.3 units. However, gene expression decreased rapidly thereafter and levels of ␤-galactosidase activity at days 14 and 21 were 4.7 ± 3.9 and 0.86 ± 0.29 units, respectively. At day 28 after the adenoviral infusion into the portal vein, ␤-galactosidase activity in the liver was not significantly different from that of naive control rats.
Development of neutralizing antibodies against adenovirus Sera were collected from rats infused intraportally with recombinant adenoviruses and neutralizing antibodies against adenovirus were examined. As shown in Figure 3 , since rats are not natural hosts of adenovirus serotype-5, there were no detectable levels of neutralizing antibodies against adenovirus in naive control rats. Development of neutralizing antibodies against adenoviruses was already observed at day 2 after the infusion, with the mean titer of neutralizing antibody being ×77. Titers of neutralizing antibody increased and reached a maximum at day 14, with the mean titer being ×2133. Neutralizing antibody titers decreased thereafter and the mean titer at day 35 was ×33.
Cytopathic effects of adenovirus in the liver Although intraportal infusion of 2 × 10 8 p.f.u. of adenoviruses into rats did not cause any deaths, we examined whether the administration of this adenoviral amount caused any cytopathic effects in the liver. Fourteen days after the adenoviral infusion, animals were killed and livers were removed. Histological analysis of the liver sections revealed viral hepatitis-like pathological changes such as infiltration of inflammatory cells predominantly at zone 1 of the liver (Figure 4a ), and hyperplastic changes and focal necrosis of hepatocytes with a disintegration of the trabecular arrangement of the normal liver cytoarchitecture at zones 2 and 3 ( Figure 4b ). These cytopathic changes gradually diminished with the passage of time and inflammatory changes had almost disappeared at day 35 after the infusion (data not shown).
Adenoviral administration-related toxicity
To examine adverse effects in animals infused intraportally with recombinant adenoviruses, serum samples were collected from rats 7 days after the infusion. As shown in Table 1 , analysis of serum biochemical parameters revealed an approximately five-and two-fold increase in LDH and AST, respectively, in rats infused with adenoviruses compared with control rats that received intraportal infusion of the same volume of phosphate-buffered saline (PBS). Serum ALT levels were also 1.5-fold higher in animals infused with adenoviruses and the difference was statistically significant compared with control animals. Serum albumin levels were significantly lower in animals infused with adenoviruses. Conversely, there were no significant differences in serum levels of bilirubin (free and conjugated), creatinine and blood urea nitrogen (BUN) between adenoviral treatment and control groups.
Readministration of adenoviruses into the portal vein
To evaluate the feasibility of re-expression of the transgene by an adenoviral vector, rats were infused intraport- ally with 2 × 10 8 p.f.u. of Adex1CAlacZ adenoviruses contained in a 500 l-inoculum volume at day 42 after the first adenoviral infusion. Animals were killed at day 49 for analysis of transgene expression. There were no cells stained blue with the X-gal staining in the liver of animals that received intraportal readministration of adenoviruses (Figure 5a ). Conversely, when animals were treated with CPA (75 mg/kg body weight) at days 37 and 41 and re-infused intraportally with adenoviruses at day 42, cells stained blue by the X-gal staining were observed in the liver (Figure 5b ). The results were confirmed quantitatively by the subsequent ONPG assay. As shown in Figure 6 , levels of lacZ gene expression in the liver of animals reinfused intraportally with adenoviruses without CPA treatment were not significantly different compared with those of animals that did not receive the adenoviral readministration. Conversely, considerable levels of lacZ gene expression were observed in the liver of animals pretreated with CPA before the readministration, with ␤-galactosidase activity being 4.2 ± 2.5 units.
Inhibition of immune responses by CPA to adenoviral readministration
To estimate the inhibitory effect of CPA treatment on humoral immune responses to adenoviral readministration, serum samples were collected from rats in the above-mentioned experiments. Titers of neutralizing antibody against adenovirus increased rapidly after the adenoviral readministration in animals that did not receive the CPA treatment, with the mean titer of neutralizing antibody being ×4480 at day 49 (7 days after the adenoviral readministration). Conversely, elevation of neutralizing antibody titers in response to adenoviral readministration was substantially suppressed by the CPA treatment, with the mean titer of neutralizing antibody in animals treated with CPA at days 37 and 41 being ×90 at day 49.
To examine whether the transient CPA treatment before the adenoviral readministration caused hepatotoxic effects, liver-related serum biochemical parameters were measured. There were no significant differences between sera of rats reinfused intraportally with adenoviruses with and without the CPA treatment in AST levels (125 ± 23 versus 143 ± 19 units per liter at 37°C) and ALT levels (38 ± 8 versus 40 ± 7 units per liter at 37°C). Serum LDH levels were significantly lower in animals that received the CPA treatment than in those that did not receive the CPA treatment (1011 ± 292 versus 1766 ± 235 units per liter at 37°C).
Figure 7 Inhibitory effect of CPA on cellular immune responses to adenoviral readministration. To examine the inhibitory effect of CPA treatment on cellular immune responses to adenoviral readministration, splenic cells were collected from rats and incubated with (a) or without (ᮀ) heatinactivated adenoviruses for 5 days and pulsed with 3 H thymidine for the last 18 h of incubation. Splenic T cells collected from animals that did not receive the CPA treatment before the adenoviral readministration proliferated markedly with the stimulation of inactivated adenoviruses, while those collected from animals that received the CPA treatment before the adenoviral readministration did not proliferate significantly with the stimulation. Values are means ± s.d. of six animals. *P Ͻ 0.001 by Student's t test.
To examine the inhibitory effect of CPA treatment on cellular immune responses to adenoviral readministration, activation of adenovirus-specific splenic T cell proliferation was estimated. Splenic cells collected from rats in the above-mentioned experiments were incubated with heat-inactivated adenoviruses, which provides a condition that favors stimulation of CD4 + T cells since inactivated viral particles are processed by antigenpresenting cells through the exogenous pathway of presentation, resulting in expression of viral peptides in association with MHC class II. As shown in Figure 7 , splenic cells from CPA-untreated animals exhibited approximately 13-fold higher proliferation with the stimulation of inactivated adenoviruses compared with those from naive control animals, while splenic cells from CPA-treated animals did not display significantly higher proliferation with the stimulants compared with those from naive animals. Values of incorporation of 3 H thymidine were significantly different in CPA-treated and untreated groups at P Ͻ 0.001 using Student's t test.
Discussion
One of the major problems with adenovirus-mediated in vivo gene transfer is that the animal becomes resistant to a second therapeutic administration of adenoviruses. 9, 11, 17, 20 This is particularly problematic in the treatment of chronic illnesses such as the single gene inherited disorders where life-long therapy will be required. Initial studies in gene therapy models developed a correlation between serum antiviral neutralizing antibody and block to gene transfer. 9, 17 This hypothesis was further evaluated in a mouse model of lung-directed gene transfer which demonstrated a direct correlation between the formation of neutralizing antibody and the activation of B cells and the T H2 subset of T helper cells to viral capsid proteins. 11, 20 Importantly, humans are natural hosts of various serotypes of adenoviruses including adenovirus serotype-2 and -5 which have been used as the backbone of currently used recombinant adenoviral vectors.
Weinberg et al 21 examined the prevalence of anti-adenovirus antibodies in 116 infants between 1 and 24 months old and showed that more than 80% of the children had been infected by adenoviruses by the age of 10 months. Rosenecker et al 22 in a noteworthy report demonstrated that IgG antibodies against adenovirus were present in 192 of 199 cystic fibrosis patients (96.5%), and were significantly higher in cystic fibrosis patients older than 7 years than in younger patients and in age matched controls. Surveillance carried out in Japan by the SRL laboratory (Hachioji, Tokyo, Japan) between 1993 and 1995 revealed that approximately 75% and 72% of Japanese possess neutralizing antibodies against adenovirus serotype-2 and -5, respectively. We have recently shown that anti-adenovirus antibody-positive human sera substantially inhibit adenovirus-mediated gene transduction. 23 In the present study, we attempted to administer a higher dose of adenoviruses. Injection of 2 × 10 9 p.f.u. of adenoviral particles into the portal vein of rats, however, killed four of six animals within 7 days, indicating the highly toxic adverse effect of an adenoviral vector. Therefore, we administered 2 × 10 8 p.f.u. of adenoviral particles into the portal vein. Although intraportal administration of this viral amount did not cause any deaths, inflammatory changes in the liver and elevation of liver functionrelated serum biochemical parameters were observed. Neutralizing antibodies against adenovirus were detectable even 2 days after the adenoviral infusion into the portal vein and reached a maximum 14 days later. LacZ gene expression in the liver was shown to be at its maximum 7 days after the adenoviral infusion into the portal vein, and then decreased rapidly probably due to cellular and humoral immune responses elicited against adenoviruses. Intraportal readministration of adenoviruses without immunosuppressive agents failed to induce re-expression of the transgene.
To inhibit the production of neutralizing antibodies against adenovirus that prevent further readministration of vectors, immunosuppressive strategies have been undertaken. It has been demonstrated that treatment regimens with immunosuppressive drugs such as cyclophosphamide, FK506, cyclosporin A and deoxyspergualin, around the time of initial exposure to adenoviruses permit prolonged transgene expression, reduce inflammation, prevent the formation of neutralizing antibodies and allow the successful readministration of adenoviral vectors. [24] [25] [26] [27] Administration of monoclonal antibodies that reduce immune responses, such as anti-CD40 ligand antibody and CTLA4Ig, around the time of the first vector administration has also been shown to be effective in preventing the formation of neutralizing antibodies against adenovirus and in permitting the successful secondary administration of adenoviral vectors. [28] [29] [30] [31] [32] The practicality of these approaches is, however, questionable because the majority of prospective gene therapy patients have already been infected with adenovirus serotype-2 and -5. Therefore, the first adenoviral administration to humans may correspond to the readministration of adenoviruses to animals. It is expected that humans may not be susceptible to immune down-regulation because activation requirements tend to be reduced in primed lymphocyte populations. 33 To evaluate the feasibility of readministration of adenoviral vectors, we performed experiments under more stringent conditions that provide a closer approximation of the expected clinical setting. Animals did not receive any immunosuppressive treatment around the time of the first adenoviral administration and did receive transient CPA treatment before the readministration of adenoviruses. Our results indicate that transient CPA administration into primed rats previously exposed to adenoviruses successfully controlled both humoral and cellular immune responses elicited by readministration of adenoviral vectors, resulting in re-expression of the transgene in the liver. Recently, Kaplan and Smith 34 have shown that transient treatment with the immunosuppressant deoxyspergualin of primed mice previously exposed intranasally to wild-type adenoviruses impaired the development of antibodies in response to a secondary intranasal challenge with adenoviral vectors, resulting in improvement of gene transfer and re-expression of the lacZ gene in the lung. These results are encouraging for clinical applications of adenoviral vectors. It is, however, true that novel strategies are still necessary for efficient readministration of adenoviral vectors, for levels of ␤-galactosidase activity in the liver and in the lung induced by readministration of adenoviral vectors with immunosuppressive agents were approximately 1/10 in both cases compared with those induced by the first adenoviral administration. Furthermore, staining patterns by Xgal histochemistry were different between liver samples obtained after the initial and second adenoviral administration. Discrete hepatocytes expressing the lacZ gene were seen throughout the liver after the initial transfection, while clusters of hepatocytes stained more weakly were observed primarily near zone 1 in the liver after the second transfection, suggesting that hepatocytes near zone 1 are more accessible to adenoviruses infused into the portal vein, and that the number of adenoviruses integrated into a single hepatocyte is smaller in rats reinfused with adenoviruses than in those initially infused with adenoviruses.
Another attempt at reducing the immunogenicity of adenovirus is the improvement of adenoviral vectors. It has been recently demonstrated that the removal of E4 region from an adenoviral vector yields significantly prolonged transgene expression in vivo with minimal virusspecific immune response. 35 Although this kind of approach may be promising, efficacy of this vector for readministration has not been evaluated. 
Materials and methods Animals
Eight-week-old female Sprague-Dawley rats were purchased from Japan SLC. (Hamamatsu, Japan). Animal experiments were performed with approved protocols and in accordance with recommendations for the proper care and use of laboratory animals.
Adenoviral vector
Adex1CAlacZ adenovirus was generously provided by Dr Izumu Saito (Institute of Medical Science, University of Tokyo, Tokyo, Japan) and details of the construction procedures have been described elsewhere. 36 This adenoviral vector carries an adenovirus serotype-5 genome lacking the E1A, E1B and E3 regions to prevent virus replication, and contains the lacZ gene as a reporter gene between the CAG promoter 37 and the rabbit ␤-globin polyadenylation signal in the place of the E1A and E1B regions. The recombinant adenovirus was propagated and isolated in 293 cells, as described previously. 38 The viral suspension was stored at −150°C until use. To titrate the viral suspension, an aliquot of virus was serially diluted and assayed for ability to form plaques on 293 cell monolayers, as described previously. 39 A single batch of high-titer adenovirus stock (4 × 10 9 p.f.u./ml) was used for subsequent experiments.
In vivo transduction, X-gal staining and ␤-galactosidase activity Rats were anesthetized with ether and 500 l of adenovirus solutions (4 × 10 8 p.f.u./ml) was infused into the portal vein. Briefly, a 26-gauge needle connected to a 1-ml syringe was inserted into the portal vein through the greater omentum, and 500 l of adenovirus solution was injected slowly into the liver through the portal vein followed by oppression for 2 min for hemostasis. Animals were killed at days 2 and 7, and then every 7 days until day 35 after the adenoviral infusion. Each group consisted of six animals. Animals were perfused with 50 ml of PBS from the portal vein when they were killed, and their livers were removed for analysis of transgene expression.
For histochemical staining, approximately half the volume of the left-lateral hepatic lobe from each animal was fixed with 4% paraformaldehyde, 0.2% glutaraldehyde and 0.02% NP-40 in 0.1 m sodium phosphate buffer (pH 7.4) for 60 min at room temperature. Livers were then sliced into 50-m thick sections with a microslicer (DTK-3000; DOSAKA EM, Kyoto, Japan). These slices were rinsed three times in PBS with 1 mm MgCl 2 and incubated overnight at 37°C in an X-gal (5-bromo-4-chloro-3-indolyl-␤-galactosidase; GIBCO, Grand Island, NY, USA) reaction mixture to detect lacZ gene expression, as described previously. 40 To measure ␤-galactosidase activity induced by lacZ gene expression quantitatively, spectrophotometric assay using o-nitrophenol-␤-d-galactopyranoside (ONPG) was performed according to the method of MacGregor et al. 41 Briefly, approximately half the volume of the left-lateral hepatic lobe from each animal was homogenized in 0.1 m sodium phosphate buffer (pH 7.4) containing 0.1 mm MnCl 2 , 2 mm MgSO 4 , 40 mm ␤-mercaptoethanol. Liver homogenates were centrifuged at 13 500 g for 15 min at 4°C. Supernatants were collected and ␤-galactosidase activity was measured by color reaction using ONPG as the substrate. Protein concentrations of the supernatants were measured using Bio-Rad (Hercules, CA, USA) protein assay with bovine serum albumin as standard. One unit of ␤-galactosidase activity was defined by the conversion of 1 nmol of ONPG/min/mg protein at 37°C.
Neutralizing antibody assay Sera were measured for neutralizing antibodies against adenovirus serotype-5, as previously described. 42 Briefly, rat serum samples were incubated for 30 min at 56°C to inactivate complement and were then diluted in DMEM medium in two-fold steps starting from 1:10 dilution. Each serum dilution (100 l) was mixed with Adex1CA-lacZ adenovirus (2 × 10 6 p.f.u. in 10 l), incubated for 1 h at 37°C, and applied to 80% confluent NIH3T3 cells in 96-well plates (2 × 10 4 cells per well). After 60 min incubation at 37°C, 100 l of DMEM containing 20% heatinactivated fetal calf serum was added to each well. On the following day, cells were fixed and stained overnight with the X-gal solution. All of the cells were stained blue in the absence of serum samples. The titer of neutralizing antibody for each sample was determined to be the reciprocal dilution that inhibited X-gal staining by 50%.
CPA administration into rat Rats were anesthetized with ether and received an intraportal infusion of recombinant adenoviruses carrying the lacZ gene (2 × 10 8 p.f.u./500 l) at day 0. CPA (75 mg/kg body weight in 500 l of PBS) injections were given via the tail vein at days 37 and 41 after the adenoviral infusion. Recombinant adenoviruses (2 × 10 8 p.f.u./ 500 l) were readministered via the portal vein at day 42. Animals were killed at day 49 for analysis of transgene expression.
Evaluation of adverse effect by adenoviral administration For evaluating the adverse effects of adenoviral administration, serum biochemical parameters including ALT, AST, LDH, albumin, bilirubin (free and conjugated), creatinine and BUN of each rat infused intraportally with recombinant adenoviruses (2 × 10 8 p.f.u./500 l) were measured 7 days after the infusion. Control animals were infused intraportally with 500 l of PBS. Each group consisted of six animals. For histological analysis of cytopathic effects caused by adenoviral administration, the left-median hepatic lobe of each animal was removed, fixed in 10% buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin.
Adenovirus-specific T cell proliferation Activation of adenovirus-specific splenic T cells was evaluated in a proliferation assay, as described previously. 34 Briefly, spleen cells were collected from each animal and plated in duplicate in the wells of 96-well, flat-bottomed plates (5 × 10 5 cells per well). The cells were incubated with medium alone (background) or stimulated with heat-inactivated (50°C for 20 min) recombinant adenoviruses at a MOI of 100 p.f.u. per cell in a total volume of 250 l per well. Cells were incubated for 5 days at 37°C/5% CO 2 and pulsed with 1 Ci per well 3 H thymidine (Amersham, Buckinghamshire, UK) for the last 18 h of incubation. Cells were harvested on to glass fiber filters with a 96-well plate cell harvester, and cell-associa-ted radioactivity was measured by liquid scintillation counting.
Statistics
Results are expressed as means ± s.d. Standard descriptive statistics and Student's t test were used. A P value of Ͻ0.05 was considered to indicate a significant difference between groups.
